web analytics

Everybody Is Talking About Rapid Test GenViro; Decision Diagnostics Corp (OTCMKTS: DECN)

7

Decision Diagnostics Corp (OTCMKTS: DECN) is an exciting stock in small caps that has quickly attracted legions of shareholders that have seen a wild ride in recent months. DECN stock has been on the move ever since the Company introduced its GenViro(TM) Corona Virus Screening Kit; a timely, simple to use, cost effective instent test kit that provides results in as little as 10.5 seconds, based on a small finger prick blood sample.

The GenViro(TM) Corona Virus Screening Kit is a “game changer” according to DECN CEO Keith Berman who notes “We’re the product of choice because it works, it works fast and because it’s affordable. The device costs $15 and the test strip kit costs $30. That’s why companies are interested. Businesses can test their workers as often as they want, in a matter of seconds, every day if they like,” said Berman. Indeed, as coronavirus spreads around the world, safely reopening the country and the world depends almost entirely on testing – widespread, affordable, accurate and accessible testing. Antibody tests and nasal swabs currently on the market are both invasive and take up to weeks for results.

Decision Diagnostics Corp (OTCMKTS: DECN) is a nationwide prescription and non-prescription diagnostics and home testing products distributor. The Company markets its GenUltimate, GenSure, PetSure (test strips for dogs and cats) and GenChoice (in FDA 510(k) review), its panacea GenUltimate TBG glucose test strips and meter (in 3rd party testing), its GenPrecis test strips and meter (for private label sale), and its GenUltimate 4Pets glucose test strips and meter for the diabetic testing of dogs, cats and horses. Decision Diagnostics is FDA approved and hase complete R&D and manufacturing facilities in South Korea.

Decision Diagnostics introduced its GenViro(TM) Corona Virus Screening Kit in March. The Company stated at the time: Today, in the third discussion of our break-through test for the coronavirus (COVID19), we present the Coronavirus test kit and the Phase 1 unit forecast. The introduction of our new screening methodology for the Coronavirus (Covid19) will provide a timely, simple to use and cost effective solution for the screening of the frightening COVID19 virus. First uses of our kits will be in pharmacies, doctor’s offices, clinics and urgent care centers, and long term care facilities. We anticipate the sale of 420,000,000 kits in the first full year of commercial sale. The company has retained FDA counsel who is in the process of securing expected emergency waiver for diagnostics and diagnostic devices.

To Find out the inside Scoop on DECN Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

DECN

GenViro(TM) Corona Virus Screening Kit has been getting noticed by main stream media with CBS New York coverfing it in a segment called: Max Minute: Diabetes Company’s Affordable, Fast Coronavirus Test May Be Key To Reopening Businesses

According to the segment: NEW YORK (CBSNewYork) – “We’re the product of choice because it works, it works fast and because it’s affordable,” According to DECN CEO Keith Berman says of the GenViro(TM) Corona Virus Screening Kit “It works by taking a finger-prick drop of blood and, through sophisticated micro-processing, arrives at a result within 30 to 45 seconds. The device costs $15 and the test strip kit costs $30. That’s why companies are interested. Businesses can test their workers as often as they want, in a matter of seconds, everyday if they like,” said Berman.

The segment ends with “It’s not free, but it is an affordable enough technology that could open up restaurants, movies, all manner of businesses and group venues. The company hopes to have all the FDA-mandated testing done by next week. If approved, Berman says they could ship as many as 100,000 units immediately and be making up to 400,000 a week within 60 days.”

Stated in a July 17 press release Decision Diagnostics has been a provider of diabetic testing products for almost two decades. Diabetic glucose test strips are a safe and effective technology used by millions of diabetics around the globe for years. The company’s patent pending impedance based technology is used on all of its Covid-19 Swift Kit test kits. DECN’s Pharma Tech Solutions subsidiary currently has two applications for FDA EUA authorization of its GenViro! blood testing kits to detect the Covid-19 virus. More recently, DECN announced it is testing and will be filing another EUA for its non-invasive saliva testing kits using the same technology consisting of testing strips and slightly modified meter software as its Covid-19 blood test kits. Decision Diagnostics plans to provide the new single use saliva testing kit option to its professional and individual use finger stick GenViro! Covid 19 Swift Kit test kits designed to identify Covid-19 viral load. Test reporting for the GenViro! finger stick kits are currently producing results at :10.5 seconds, and initial testing completed on the saliva version of the kit should yield even faster results since the saliva testing will not require any sample correction. The GenViro! Covid-19 Saliva Swift Kit is completely non-invasive.

We have a Monster Pick Coming. Subscribe Right Now!

Currently DECN still carries the skull and crossbones designation from otcmarkets that it received during the stock suspension which it has not recovered from. DECN is an exciting story in small caps establishing itself as a volume leader and proven runner. According to DECN its GenViro(TM) Corona Virus Screening Kit easily tops anything on the market providing results in as little as 10.5 seconds, based on a small finger prick blood sample. The method is safe, effective, and its biggest benefit to the healthcare system is that the device can be used to screen out the 97% or 98% of those tested that are negative for COVID-19.  DECN’s Pharma Tech Solutions subsidiary currently has two applications for FDA EUA authorization of its GenViro! blood testing kits to detect the Covid-19 virus. More recently, DECN announced it is testing and will be filing another EUA for its non-invasive saliva testing kits using the same technology consisting of testing strips and slightly modified meter software as its Covid-19 blood test kits. Once and if they pass the FDA data testing guidelines given after the PRE-EUA approval letter, they would be able to manufacture, sell and distribute immediately and current price levels could be history. Microcapdaily has been reporting on DECN since the stock was .05. We will be updating on DECN when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with DECN.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in DECN either long or short and we have not been compensated for this article.

Share.

7 Comments

  1. Dear Mr Young, I’ve been a patient Decn shareholder for many many months, why hasn’t this stock been noticed by major players yet.. with their so called game changing technology. Please reply…RB jr.

  2. The problem is this is an 100% scam ..do your Due Diligence it’s not too hard to find. Try Iub for the quick info

  3. Basically the skull and cross bone was put on this stock by the SEC when they were doing a purge of questionable Covid startups. Yes the initial statement by the CEO seemed outlandish but the reality it isn’t. Mr. Berman had to go to both the SEC and the FDA to explain in detail how the technology works (that should have only been a FDA requirement which Berman is satisfying) and even after submitting a rebuttal to the SEC they do not want to admit any wrong doing on their part and instead sent a counter rebuttal that just rehashed their failed logic from their first document. DECN now has a clear path to get the SEC skull and crossbones removed and are pursuing that requirement. I second Willie Mays comment on why write such a detailed report if you yourself don’t see a path forward.

  4. Tarun Ramnani on

    Oftentimes the road to success is paved with obstacles which through perseverance can be overcome and success should not be measured by what they have achieved but what they have overcome. If the product works and functions and delivers its intended and stated results then ultimately it will reach its target audience. Hopefully the agencies that are meant to safeguard the public are not the ones to hold back products from reaching the marketplace simply because their forward looking statements or technology is new or simply because their approach takes a different route then a established route.

  5. It seems more like the SEC is on a witch hunt for small cap companies. I understand protecting investors but to “grey list” companies that are using tech that are a Google Scholar search away is down right ludicrous.

Leave A Reply

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.